Oral hymecromone decreases hyaluronan in human study participants

BACKGROUND: Hyaluronan (HA), an extracellular matrix glycosaminoglycan, has been implicated in the pathophysiology of COVID-19 infection, pulmonary hypertension, pulmonary fibrosis, and other diseases, but is not targeted by any approved drugs. We asked whether hymecromone (4-methylumbelliferone [4-...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosser, Joelle I., Nagy, Nadine, Goel, Riya, Kaber, Gernot, Demirdjian, Sally, Saxena, Jamie, Bollyky, Jennifer B., Frymoyer, Adam R., Pacheco-Navarro, Ana E., Burgener, Elizabeth B., Rajadas, Jayakumar, Wang, Zhe, Arbach, Olga, Dunn, Colleen E., Kalinowski, Anissa, Milla, Carlos E., Bollyky, Paul L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057598/
https://www.ncbi.nlm.nih.gov/pubmed/35499083
http://dx.doi.org/10.1172/JCI157983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057598/
https://www.ncbi.nlm.nih.gov/pubmed/35499083
http://dx.doi.org/10.1172/JCI157983

Ejemplares similares